• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
【24h】

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer

机译：非小细胞肺癌培养治疗治疗长期响应者的预测因素

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We determined the clinical characteristics and predictive factors of long-term response to pemetrexed maintenance therapy as first-line treatment for non-small cell lung cancer (NSCLC). A total of 950 advanced NSCLC patients received pemetrexed (500 mg/m2 ) plus cisplatin (60 mg/m2?10 (M10, n =?65). The M10 group had a higher proportion of patients with stage M1a (intrathoracic metastasis alone) and exhibited lower levels of thymidylate synthase (TS) than the F10 group (median H-score 10.0% vs. 60.0%; P =?0.031). Further subgrouping identified extreme responders: ≤ 7 (F7, n =?101) and?≥?20 (M20, n =?26) cycles. The M20 group showed lower mean serum CEA levels before (17.5 vs. 147.0; P =?0.099) and after (6.9 vs. 53.2; P =?0.001) Pem-Cis treatment, and a higher incidence of normalization after Pem-Cis (abnormal 41.7% vs. 68.5%; P =?0.015). M1a stage, normalization of CEA levels after Pem-Cis, and lower TS H-score were predictors of progression-free survival in patients administered pemetrexed maintenance. M1a stage and lower TS expression were predictors of long-term response to pemetrexed maintenance. CEA normalization after Pem-Cis could be an additional surrogate marker of positive response to long-term treatment. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：我们确定了对非小细胞肺癌（NSCLC）的一线治疗的临床特征和预测因素。总共950名高级NSCLC患者接受磷光络（500mg / m2）加顺铂（60mg / m 2→10（M10，n =Δ65）。M10组具有较高比例的M1A患者（单独的胃系甲转移）并表现出低于F10基团的胸苷合酶（TS）较低（中位数H-Score 10.0％vs.60.0％; P = 0.031）。另外的子组识别的极端响应者：≤7（F7，n = 101）和？ ≥20（M20，N =Δ26）循环。M20组之前显示出较低的平均血清CEA水平（17.5 vs.147.0; p = 0.099）和之后（6.9与53.2; p = 0.001）PEM-CIS治疗和PEM-CIS后的正常化发生率较高（异常41.7％与68.5％; P = 0.015）。PEM-CIS后，CEA水平的标准化，并且降低TS H-得分是进展的预测因子 - 患者的自由生存患者施用的培养基维持。M1A阶段和下部TS表达是对Pemetrexed维护的长期反应的预测因子。CEA标准化在PEM-CIS之后可以是另一种替代MA对长期治疗的积极反应的rker。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号